基因治疗市场－全球产业规模、份额、趋势、机会及预测（依载体类型、递送方式、适应症、地区及竞争情况划分，2020-2030 年预测）

2024 年全球基因治疗市场价值为 65.4 亿美元，预计到 2030 年将达到 112.9 亿美元，预测期内复合年增长率为 9.53%。基因疗法被描述为透过改变、替换或补充导致疾病的缺失或缺陷的基因组合来治疗疾病。基因治疗已成为对抗退化性疾病最令人嚮往的研究目标之一。全球范围内癌症和其他慢性疾病病例数量的增加推动了对基因治疗的需求。基因治疗的进步预计将在未来几年获得批准，从而促进预测期内基因治疗市场的成长。基因疗法旨在透过改变遗传讯息来治疗疾病，例如使功能失调的基因失去活性或用健康的基因副本替换致病基因。基因疗法已被用于治疗多种疾病，并已被证明是有效的。这种治疗方法可以治疗糖尿病、癌症、心臟病和爱滋病等疾病。

市场概览
预测期	2026-2030
2024年市场规模	65.4亿美元
2030年市场规模	112.9亿美元
2025-2030 年复合年增长率	9.53%
成长最快的领域	非病毒载体
最大的市场	北美洲

预计强大的基因治疗产品线将在预测期内推动市场成长。研究人员正在积极致力于使基因疗法在临床环境中更容易获得。许多大学和研究机构正在开发各种各样的基因疗法产品，预计这些产品将在未来几年为创造收入做出重大贡献。自 FDA 批准首个基因疗法以来，2017 年至 2018 年间，基因疗法临床试验的数量显着增加。根据美国基因与细胞治疗学会（ASGCT）统计，目前约有1986种基因治疗产品正在开发中，包括CAR-T细胞疗法和其他基因改造细胞疗法，进一步加速了市场扩张。

关键市场驱动因素

遗传学研究的进展

主要市场挑战

技术复杂性

主要市场趋势

扩大治疗目标

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：临床试验分析

第 4 章：1 正在进行的临床试验

第 4 章：2 项已完成的临床试验

第四章：3 项终止的临床试验

第四章：依开发阶段细分的管道

第 4 章：5 条管道依状态细分

第 4 章：6 个研究管道细分（依研究类型）

第四章：7 个管道细分（按地区）

第 4 章：8 项临床试验热图

第五章：顾客之声

第六章：全球基因治疗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按载体类型（病毒载体、非病毒载体）
  • 依递送方式（体内、体外）
  • 按适应症（罕见疾病、癌症、神经系统疾病、其他）
  • 按地区（北美、欧洲、亚太、南美、中东和非洲）
  • 按公司分类（2024）
• 市场地图
• 依向量类型
• 按交付方式
• 按适应症
• 按地区

第七章：北美基因治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第八章：欧洲基因治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第九章：亚太基因治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第十章：南美洲基因治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 11 章：中东和非洲基因治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 12 章：市场动态

• 驱动程式
• 挑战

第十三章：市场趋势与发展

• 近期发展
• 併购
• 产品发布

第 14 章：全球基因治疗市场：SWOT 分析

第十五章：资金分析

第 16 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 17 章：竞争格局

• REGENXBIO Inc.
• Oxford Biomedica PLC.
• Voyager Therapeutics Inc.
• Human Stem Cells Institute
• Dimension Therapeutics, Inc.
• Bristol-Myers Squibb Company
• Sanofi
• F. Hoffmann-La Roche ltd.
• bluebird bio, Inc.
• Novartis AG
• Uniqure NV

第 16 章：策略建议

第17章调查会社について・免责事项

Global Gene Therapy Market was valued at USD 6.54 Billion in 2024 and is expected to reach USD 11.29 Billion by 2030 with a CAGR of 9.53% during the forecast period. The gene therapy is described as the treatment of an illness by changing, replacing, or supplementing a missing or defective genetic combination that is responsible for the disease. The gene therapy has become one of the most desirable research goals in the fight against degenerative illnesses. The need for gene therapy is being driven by an increase in the number of cases of cancer and other chronic diseases all across the world. The advancements in gene therapies are projected to be approved in the upcoming years, contributing to the gene therapy market's growth during the forecast period. The gene therapies are designed to treat diseases by altering genetic information, such as inactivating malfunctioning genes or replacing a disease-causing gene with a healthy copy of gene. The gene therapy is being utilized to treat a variety of disorders and has demonstrated to be effective. This form of treatment can cure diseases such as diabetes, cancer, heart disease, and AIDS.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 6.54 Billion
Market Size 2030	USD 11.29 Billion
CAGR 2025-2030	9.53%
Fastest Growing Segment	Non-viral vectors
Largest Market	North America

The strong pipeline of gene therapy products is anticipated to drive market growth over the forecast period. Researchers are actively working to make gene therapy more accessible in clinical settings. Numerous universities and research institutes are developing a diverse range of gene therapy products, which is expected to contribute significantly to revenue generation in the coming years. The number of clinical trials for gene therapy saw a notable increase between 2017 and 2018, following the FDA's approval of the first gene therapy. According to the American Society of Gene & Cell Therapy (ASGCT), approximately 1,986 gene therapy products, including CAR T-cell therapies and other genetically modified cell treatments, are currently in development, further accelerating market expansion.

Key Market Drivers

Advancements in Genetic Research

The increasing understanding of the genetic basis of diseases has enabled scientists to identify specific genes responsible for various disorders. This knowledge is crucial for designing targeted gene therapies that can correct or replace defective genes, addressing the root cause of diseases. Genetic research has identified specific genetic mutations or abnormalities that contribute to various diseases, such as inherited genetic disorders and certain types of cancer. This has provided gene therapists with clear therapeutic targets, allowing them to develop more precise and effective treatments. Advancements in gene editing technologies, such as CRISPR-Cas9, TALENs, and zinc finger nucleases, have revolutionized gene therapy. These techniques enable scientists to accurately and efficiently edit or modify genes, opening up new possibilities for treating genetic disorders. Genetic research has paved the way for personalized medicine, where treatments are tailored to an individual's genetic makeup. This approach enhances the effectiveness of gene therapies by considering genetic variations that might affect treatment outcomes, leading to better patient responses and reduced adverse effects. Genetic research has facilitated the development of advanced delivery systems that help target specific tissues or cells with greater precision. This has improved the efficiency of gene therapy treatments, minimized off-target effects and enhancing therapeutic outcomes. The promising outcomes of genetic research have attracted substantial investment in the gene therapy sector. As the potential of gene therapies becomes more apparent, investors are more willing to fund research and development, driving innovation and market growth. For example, in December 2023, the U.S. FDA approved a gene therapy for sickle cell disease, marking the first-ever gene therapy based on CRISPR gene editing. Such groundbreaking advancements and product launches are expected to drive market growth over the forecast period.

Key Market Challenges

Technical Complexity

Developing effective gene therapies requires a deep understanding of genetics, molecular biology, and complex cellular processes. The technical complexity of designing therapies that accurately target and modify specific genes can lead to prolonged research and development timelines. Getting therapeutic genes into target cells poses a significant challenge. Developing efficient and safe delivery systems, such as viral vectors or nanoparticles, requires extensive optimization and testing. Technical difficulties in achieving precise and controlled delivery can affect the success of gene therapies. The interactions between modified genes and the host organism can sometimes lead to unintended consequences. Technical complexities can make it difficult to predict the outcomes of gene therapies accurately, leading to safety concerns and regulatory challenges. Regulatory agencies require a high level of safety and efficacy data for gene therapy products due to their complexity and potential risks. Navigating the regulatory pathway for gene therapies can be challenging and time-consuming, hindering market growth. Manufacturing gene therapy products in a consistent and scalable manner is challenging due to the complexity of biological processes involved. Ensuring the quality, safety, and stability of gene therapies at a commercial scale can be technically demanding and expensive.

Key Market Trends

Expanding Therapeutic Targets

Identifying new therapeutic targets means gene therapy can be applied to a wider range of medical conditions beyond traditional monogenic disorders. This diversity includes complex diseases like cancer, cardiovascular diseases, neurodegenerative disorders, and rare diseases, expanding the addressable patient population. The availability of gene therapies for multiple therapeutic targets attracts a larger patient base, driving market growth by increasing the potential customer pool and commercial opportunities. The discovery of new therapeutic targets stimulates research and development efforts by both established pharmaceutical companies and smaller biotechnology firms. This influx of investment fuels innovation and accelerates the development of gene therapies for various indications. Expanding therapeutic targets leads to a more diverse portfolio of clinical trials. This diversity enhances the clinical trial landscape, allowing researchers to explore different patient populations, endpoints, and treatment approaches, ultimately advancing the field. As gene therapies target a wider array of diseases, regulatory agencies may provide specialized pathways or guidelines for specific indications. This attention can expedite regulatory approval processes and facilitate market entry. The availability of gene therapies for more common and relatable diseases can increase public awareness and acceptance of the technology. Positive outcomes in well-known conditions can build trust and reduce skepticism. Expanding therapeutic targets can lead to collaborations between academic researchers, industry partners, and patient advocacy groups. Collaborations strengthen expertise, resources, and support networks, fostering innovation and growth. The potential for gene therapies to target various indications attracts diverse investors interested in contributing to the development of treatments for specific diseases, fostering a competitive market landscape.

Key Market Players

• REGENXBIO Inc.
• Oxford Biomedica PLC.
• Voyager Therapeutics Inc.
• Human Stem Cells Institute
• Dimension Therapeutics, Inc.
• Bristol-Myers Squibb Company
• Sanofi
• F. Hoffmann-La Roche Ltd
• bluebird bio, Inc.
• Novartis AG
• uniQure NV.

Report Scope:

In this report, the Global Gene Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gene Therapy Market, By Vector Type:

• Viral Vector
• Non-Viral Vector

Gene Therapy Market, By Delivery Method:

• In-Vivo
• Ex-Vivo

Gene Therapy Market, By Indication:

• Rare Diseases
• Cancer
• Neurological Diseases
• Others

Gene Therapy Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gene Therapy Market.

Available Customizations:

Global Gene Therapy market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Clinical Trial Analysis

4.1 Ongoing Clinical Trials

4.2 Completed Clinical Trials

4.3 Terminated Clinical Trials

4.4 Breakdown of Pipeline, By Development Phase

4.5 Breakdown of Pipeline, By Status

4.6 Breakdown of Pipeline, By Study Type

4.7 Breakdown of Pipeline, By Region

4.8 Clinical Trials Heat Map

5. Voice of Customer

6. Global Gene Therapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
  • 6.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
  • 6.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
  • 6.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  • 6.2.5. By Company (2024)
• 6.3. Market Map
• 6.3.1 By Vector Type
• 6.3.2 By Delivery Method
• 6.3.3 By Indication
• 6.3.4 By Region

7. North America Gene Therapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
  • 7.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
  • 7.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Gene Therapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Vector Type
      • 7.3.1.2.2. By Delivery Method
      • 7.3.1.2.3. By Indication
  • 7.3.2. Canada Gene Therapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Vector Type
      • 7.3.2.2.2. By Delivery Method
      • 7.3.2.2.3. By Indication
  • 7.3.3. Mexico Gene Therapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Vector Type
      • 7.3.3.2.2. By Delivery Method
      • 7.3.3.2.3. By Indication

8. Europe Gene Therapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
  • 8.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
  • 8.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
  • 8.2.4. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France Gene Therapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Vector Type
      • 8.3.1.2.2. By Delivery Method
      • 8.3.1.2.3. By Indication
  • 8.3.2. Germany Gene Therapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Vector Type
      • 8.3.2.2.2. By Delivery Method
      • 8.3.2.2.3. By Indication
  • 8.3.3. United Kingdom Gene Therapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Vector Type
      • 8.3.3.2.2. By Delivery Method
      • 8.3.3.2.3. By Indication
  • 8.3.4. Italy Gene Therapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Vector Type
      • 8.3.4.2.2. By Delivery Method
      • 8.3.4.2.3. By Indication
  • 8.3.5. Spain Gene Therapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Vector Type
      • 8.3.5.2.2. By Delivery Method
      • 8.3.5.2.3. By Indication

9. Asia-Pacific Gene Therapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
  • 9.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
  • 9.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
  • 9.2.4. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China Gene Therapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Vector Type
      • 9.3.1.2.2. By Delivery Method
      • 9.3.1.2.3. By Indication
  • 9.3.2. India Gene Therapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Vector Type
      • 9.3.2.2.2. By Delivery Method
      • 9.3.2.2.3. By Indication
  • 9.3.3. Japan Gene Therapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Vector Type
      • 9.3.3.2.2. By Delivery Method
      • 9.3.3.2.3. By Indication
  • 9.3.4. South Korea Gene Therapy Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Vector Type
      • 9.3.4.2.2. By Delivery Method
      • 9.3.4.2.3. By Indication
  • 9.3.5. Australia Gene Therapy Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Vector Type
      • 9.3.5.2.2. By Delivery Method
      • 9.3.5.2.3. By Indication

10. South America Gene Therapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
  • 10.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
  • 10.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Gene Therapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Vector Type
      • 10.3.1.2.2. By Delivery Method
      • 10.3.1.2.3. By Indication
  • 10.3.2. Argentina Gene Therapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Vector Type
      • 10.3.2.2.2. By Delivery Method
      • 10.3.2.2.3. By Indication
  • 10.3.3. Colombia Gene Therapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Vector Type
      • 10.3.3.2.2. By Delivery Method
      • 10.3.3.2.3. By Indication

11. Middle East and Africa Gene Therapy Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
  • 11.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
  • 11.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
  • 11.2.4. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Gene Therapy Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Vector Type
      • 11.3.1.2.2. By Delivery Method
      • 11.3.1.2.3. By Indication
  • 11.3.2. Saudi Arabia Gene Therapy Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Vector Type
      • 11.3.2.2.2. By Delivery Method
      • 11.3.2.2.3. By Indication
  • 11.3.3. UAE Gene Therapy Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Vector Type
      • 11.3.3.2.2. By Delivery Method
      • 11.3.3.2.3. By Indication

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Recent Development
• 13.2. Mergers & Acquisitions
• 13.3. Product Launches

14. Global Gene Therapy Market: SWOT Analysis

15. Funding Analysis

16. Porter's Five Forces Analysis

• 16.1. Competition in the Industry
• 16.2. Potential of New Entrants
• 16.3. Power of Suppliers
• 16.4. Power of Customers
• 16.5. Threat of Substitute Products

17. Competitive Landscape

• 17.1. REGENXBIO Inc.
  • 17.1.1. Business Overview
  • 17.1.2. Company Snapshot
  • 17.1.3. Products & Services
  • 17.1.4. Financials (As Reported)
  • 17.1.5. Recent Developments
  • 17.1.6. Key Personnel Details
  • 17.1.7. SWOT Analysis
• 17.2. Oxford Biomedica PLC.
• 17.3. Voyager Therapeutics Inc.
• 17.4. Human Stem Cells Institute
• 17.5. Dimension Therapeutics, Inc.
• 17.6. Bristol-Myers Squibb Company
• 17.7. Sanofi
• 17.8. F. Hoffmann-La Roche ltd.
• 17.9. bluebird bio, Inc.
• 17.10. Novartis AG
• 17.11. Uniqure N.V.

16. Strategic Recommendations

17. About Us & Disclaimer